acura pharmaceuticals, inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. we have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • limitx™ technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. in 2014, we were awarded a $300,000 grant from the national institute on drug abuse to advance early stage development of our limitx technology. • aversion® technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief. oxaydo® tablets (oxycodone hcl, cii), is the first approved product using aversion® in the united states. on january 7, 2015, we entered int
Company profile
Ticker
ACUR
Exchange
Website
CEO
Robert Jones
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HALSEY DRUG CO INC/NEW
SEC CIK
Corporate docs
IRS number
110853640
ACUR stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Changes in Registrant's Certifying Accountant
2 Feb 24
8-K
Entry into a Material Definitive Agreement
10 Jan 24
8-K
Entry into a Material Definitive Agreement
21 Dec 23
8-K
Entry into a Material Definitive Agreement
6 Dec 23
NT 10-Q
Notice of late quarterly filing
3 Nov 23
8-K
Entry into a Material Definitive Agreement
12 Oct 23
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.00 k | 65.00 k | 65.00 k | 65.00 k | 65.00 k | 65.00 k |
Cash burn (monthly) | 8.00 k | 29.00 k | 79.00 k | 117.83 k | 142.00 k | 61.83 k |
Cash used (since last report) | 223.01 k | 808.42 k | 2.20 mm | 3.28 mm | 3.96 mm | 1.72 mm |
Cash remaining | -158.01 k | -743.42 k | -2.14 mm | -3.22 mm | -3.89 mm | -1.66 mm |
Runway (months of cash) | -19.8 | -25.6 | -27.1 | -27.3 | -27.4 | -26.8 |
Institutional ownership, Q2 2022
79.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 21.49 mm |
Total shares | 52.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schutte John | 52.98 mm | $21.49 mm |
Captrust Financial Advisors | 245.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Bruce F Wesson | Common Stock | Option exercise | Acquire M | No | No | 0 | 37,500 | 0.00 | 829,548 |
2 Jan 24 | Bruce F Wesson | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 12,500 | 0.00 | 0 |
2 Jan 24 | Bruce F Wesson | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 37,500 | 0.00 | 12,500 |
2 Jan 24 | Immanuel Thangaraj | Common Stock | Option exercise | Acquire M | No | No | 0 | 50,000 | 0.00 | 447,647 |
2 Jan 24 | Immanuel Thangaraj | RSU Common Stock | Grant | Dispose A | No | No | 0 | 50,000 | 0.00 | 50,000 |
2 Jan 24 | Immanuel Thangaraj | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 50,000 | 0.00 | 0 |
2 Jan 24 | William G Skelly | Common Stock | Option exercise | Acquire M | No | No | 0 | 50,000 | 0.00 | 575,989 |
2 Jan 24 | William G Skelly | RSU Common Stock | Grant | Dispose A | No | No | 0 | 50,000 | 0.00 | 50,000 |
2 Jan 24 | William G Skelly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 50,000 | 0.00 | 0 |
2 Jan 24 | George K Ross | Common Stock | Option exercise | Acquire M | No | No | 0 | 50,000 | 0.00 | 495,503 |